16 September 2026 editorial review · Item
Sana Biotechnology SC451 (hypoimmune stem-cell islets): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
-
Disposition: corrected after additional opening-summary and ranking QA; current item
lastReviewed: 2026-09-16. -
Claim check: Distinguished UP421 donor-islet proof from the still-pre-IND SC451 iPSC product. The first NEJM case and July letter/sponsor follow-up concern one low-dose recipient who remained on insulin. Full July letter retrieval was limited; sponsor details remain attributed rather than treated as an independent full-paper review.
-
Registry NCT06239636: RECRUITING; updated 2024-12-11; enrollment 2 (ESTIMATED); primary completion 2025-05 (ESTIMATED); results not posted in retrieved record.
-
Primary publication/regulatory sources checked or consulted: NEJMc2604408; PMID 40757665; 09636897251394787; s41587-019-0016-3.
-
Programme/sponsor/conference source boundary: Sana Biotechnology Announces Follow-On Publication in the New England Journal of Medicine Highlighting Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes (manufacturer); Sana Biotechnology and Mayo Clinic Announce Strategic Collaboration Focused on Improving Care in Type 1 Diabetes and Accelerating Development of SC451 (manufacturer).
-
Additional correction: evidence badge now preclinical; all six criteria and their scores apply to SC451 itself. Removed inherited UP421 age and treatment regions, unsupported strongest/longest comparisons, and claims that immune evasion is proven for SC451. UP421 clinical observations remain explicitly separate context. Detailed July follow-up is attributed to the company because full letter retrieval remained limited.
-
Fresh primary status evidence: Sana 10 August 2026 Q2 update describes preparation for IND and Phase 1/2; SC451 registry name search repeated 16 September returned 0. Search absence is not worldwide proof; stage 0 was retained from primary development evidence, not inferred from calendar dates.